Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Iovance Biotherapeutics (IOVA) over the last 12 years, with Q3 2025 value amounting to -$91.3 million.

  • Iovance Biotherapeutics' Income towards Parent Company fell 923.14% to -$91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$397.7 million, marking a year-over-year increase of 299.44%. This contributed to the annual value of -$372.2 million for FY2024, which is 1617.94% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Income towards Parent Company stood at -$91.3 million, which was down 923.14% from -$111.7 million recorded in Q2 2025.
  • Iovance Biotherapeutics' Income towards Parent Company's 5-year high stood at -$78.6 million during Q4 2024, with a 5-year trough of -$116.4 million in Q4 2023.
  • Its 3-year average for Income towards Parent Company is -$103.2 million, with a median of -$107.4 million in 2023.
  • In the last 5 years, Iovance Biotherapeutics' Income towards Parent Company surged by 3247.31% in 2024 and then tumbled by 1505.37% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Income towards Parent Company (Quarter) stood at -$116.4 million in 2023, then skyrocketed by 32.47% to -$78.6 million in 2024, then fell by 16.14% to -$91.3 million in 2025.
  • Its Income towards Parent Company was -$91.3 million in Q3 2025, compared to -$111.7 million in Q2 2025 and -$116.2 million in Q1 2025.